International regulatory landscape and integration of corrective genome editing into in vitro fertilization
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Abstract
Genome editing technology, including zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeat (CRISPR)/Cas, has enabled far more efficient genetic engineering even in non-human primates. This biotechnology is more likely to develop into medicine for preventing a genetic disease if corrective genome editing is integrated into assisted reproductive technology, represented by in vitro fertilization. Although rapid advances in genome editing are expected to make germline gene correction feasible in a clinical setting, there are many issues that still need to be addressed before this could occur. We herein examine current status of genome editing in mammalian embryonic stem cells and zygotes and discuss potential issues in the international regulatory landscape regarding human germline gene modification. Moreover, we address some ethical and social issues that would be raised when each country considers whether genome editing-mediated germline gene correction for preventive medicine should be permitted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“About 30 nations currently have legislation that directly or indirectly bars all clinical uses of germline editing 1 , and they might choose to continue the morato rium indefinitely or implement a permanent ban.”
From Adopt a moratorium on heritable genome editing (2019) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Their review of 39 countries identified 29 that banned heritable human genome modification (by legisla-tion or guidelines), and one country-the United Statesas having restrictive guidelines.Nine countries were said to have policies that were ambiguous.”
From Human Germline and Heritable Genome Editing: The Global Policy Landscape (2020) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering
Gaj, T., Gersbach, C. A., & Barbas, C. F. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.04.004 · Cited by 3,820
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
CRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153 · cited 1×
“Present-day genome editing technology, such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeat (CRISPR)/Cas system, have achieved far more efficient genetic engineering in higher organisms than the older techniques [20…”
BackgroundGenome editing with engineered zinc finger nucleases
Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S., & Gregory, P. D. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2842 · Cited by 2,285
Improving CRISPR-Cas nuclease specificity using truncated guide RNAs
Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2808 · Cited by 1,993 · cited 1×
“However, Cas9 has been rapidly improved, demonstrating that the combination of a Cas9 nickase mutant and paired gRNAs, the truncation of gRNAs, or the fusion of inactive Cas9 to Fok I nuclease can improve the specificity of targeted gene modification [42,77,78].”
BackgroundTALENs: A widely applicable technology for targeted genome editing
Joung, J. K., & Sander, J. D. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3486 · Cited by 1,650 · cited 1×
“Present-day genome editing technology, such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeat (CRISPR)/Cas system, have achieved far more efficient genetic engineering in higher organisms than the older techniques [20…”
BackgroundHighly efficient endogenous human gene correction using designed zinc-finger nucleases
Urnov, F. D., Miller, J. C., Lee, Y.-L., Beausejour, C. M., Rock, J. M., Augustus, S., Jamieson, A. C., Porteus, M. H., Gregory, P. D., & Holmes, M. C. (2005) · Nature · doi:10.1038/nature03556 · Cited by 1,641
Yang, H., Wang, H., Shivalila, C. S., Cheng, A. W., Shi, L., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.08.022 · Cited by 1,596
Schwank, G., Koo, B.-K., Sasselli, V., Dekkers, J. F., Heo, I., Demircan, T., Sasaki, N., Boymans, S., Cuppen, E., van der Ent, C. K., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.11.002 · Cited by 1,424 · cited 1×
“With regard to CRISPR/Cas9, it was demonstrated that those engineered nucleases can correct a mutation in intestinal stem cells derived from patients with cystic fibrosis [31].”
Background
Research works printed but not linked: 1
- Lokody I: Genetic therapies: Correcting genetic defects with CRISPRCas9. Nat Rev Genet 2013, 15:63-63.
Cited by
Adopt a moratorium on heritable genome editing
Lander, E. S., Baylis, F., Zhang, F., Charpentier, E., Berg, P., Bourgain, C., Friedrich, B., Joung, J. K., Li, J., Liu, D., et al. (2019) · Nature · doi:10.1038/d41586-019-00726-5 · Cited by 512
Ormond, K. E., Mortlock, D. P., Scholes, D. T., Bombard, Y., Brody, L. C., Faucett, W. A., Garrison, N. A., Hercher, L., Isasi, R., Middleton, A., et al. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.06.012 · Cited by 252
Rasul, M. F., Hussen, B. M., Salihi, A., Ismael, B. S., Jalal, P. J., Zanichelli, A., Jamali, E., Baniahmad, A., Ghafouri-Fard, S., Basiri, A., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01487-4 · Cited by 171
Human Germline and Heritable Genome Editing: The Global Policy Landscape
Baylis, F., Darnovsky, M., Hasson, K., & Krahn, T. M. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0082 · Cited by 155
“This omission is particularly striking in the articles by Araki and Ishii (2014) and Ishii (2015 and 2017), which conclude that 29 countries prohibit heritable human genome editing.”
Therapeutic gene editing: delivery and regulatory perspectives
Shim, G., Kim, D., Park, G. T., Jin, H., Suh, S.-K., & Oh, Y.-K. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.2 · Cited by 121
Metadata
- Authors
- Araki, M., & Ishii, T.
- Affiliations
- Hokkaido University (JP)
- Corresponding author
- Ishii, Tetsuya
- ORCID
- Ishii, Tetsuya
- Venue
- Reproductive Biology and Endocrinology
- Published
- 2014
- Volume
- 12
- Issue
- 1
- Pages
- 108
- ISSN
- 1477-7827 (ISSN-L)
- PMC
- PMC4251934
- OpenAlex
- W2160704433
- Cited by
- 150
- References
- 82
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 2 · 2023: 7 · 2022: 16 · 2021: 13 · 2020: 23 · 2019: 22 · 2018: 17 · 2017: 15 · 2016: 13 · 2015: 8
- FWCI
- 1.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Reproductive Biology and Endocrinology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by)
- Hokkaido University Collection of Scholarly and Academic Papers (Hokkaido University) (submittedVersion, cc-by)
- Funders
- Japan Society for the Promotion of Science (26460586)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Animal Genetics and Reproduction
- Keywords
- genome editing, in vitro fertilization, assisted reproduction, CRISPR-Cas, zinc finger nucleases, TALEN, zygote, genetic disease prevention, social problems
- MeSH terms
- Animals, Fertilization in Vitro, Genetic Engineering, Health Policy, Humans, Global Health, Genome, Human, Genomics, Genetic Diseases, Inborn, Targeted Gene Repair, Translational Research, Biomedical, Stem Cell Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: International regulatory landscape and integration of corrective genome editing into in vitro fertilization. https://app.cochat.ai/papers/10.1186/1477-7827-12-108
- The paper
- Araki, M., & Ishii, T. (2014). International regulatory landscape and integration of corrective genome editing into in vitro fertilization. Reproductive Biology and Endocrinology. https://doi.org/10.1186/1477-7827-12-108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.